LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the first quarter ended March 31, 2023 on Tuesday, May 9, 2023 and…Read More
Related Posts

Sirnaomics to Present Latest Developments on Two Proprietary Delivery Platforms at Upcoming Industry Conferences
HONG KONG, Germantown, Md. and SUZHOU, China, July 12, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical…

Newborn Screening Market to Reach USD 33 Bn CAGR of 11 from 2021 to 2031…
Wilmington, Delaware, United States, May 11, 2023 (GLOBE NEWSWIRE) -- The market for newborn screening will reach USD 3.3 billion by 2031, expanding at a CAGR of 11% over that…

SourceOne Global Partners celebrates 20year anniversary reflecting on pioneering a bestinclass high bioavailability technology platform
CHICAGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- SourceOne Global Partners is proud to announce the launch of new, science-backed product solutions as it celebrates twenty years as a leading supplier…